Course:PHAR501/Pulmonary
Pulmonary Therapeutics | |
---|---|
PHAR 501 | |
Section: | |
Instructor: | Dr. James McCormack |
Email: | james.mccormack@ubc.ca |
Office: | PHRM 3519 |
Office Hours: | |
Class Schedule: | 1300-1700h, 30AUG12 |
Classroom: | Pharm.D. Seminar Room |
Important Course Pages | |
Syllabus | |
Lecture Notes | |
Assignments | |
Course Discussion | |
Pulmonary Therapeutics
Updated Aug/Sept 2012
Instructor
James McCormack, B.Sc., B.Sc.(Pharm), Pharm.D.
james.mccormack@ubc.ca
phone 604-603-7898
Section Objectives
The overall objective of this section is to have the Pharm. D. student design an effective, safe and cost-effective therapeutic plan for the treatment of patients with respiratory disease. The approach to the patient should follow the pharmacist’s workup of drug therapy.
This therapeutic plan should include:
- establishing achievable short term and long term goals of therapy
- choosing appropriate empiric drug therapy for the treatment of asthma (acute/chronic/adult/pediatric), bronchitis, and emphysema
- appropriate dosage recommendations based on patient variables such as age, weight, severity of disease, and organ function
- measuring the effectiveness of drug therapy by monitoring patient symptoms and objective pulmonary tests
- minimizing the risk of toxicity by understanding the toxicities of drug therapy and knowing what to do should they occur
- determining cost considerations of various type of therapy for pulmonary disease
- counselling patients on the appropriate use of inhalers
- understanding the clinically important drug/drug and drug/food interactions and what to do should they occur
- explaining the differences and similarities between drugs/products in the same therapeutic class and differentiating between these agents in the treatment of acute versus chronic asthma/COPD
- beta agonists(inhaled, oral, and parenteral)
- corticosteroids(inhaled, oral, and parenteral)
- leukotriene antagonists
- ipratropium, tiotropium
- cromolyn, ketotifen
- theophyllines and related salts (including different product formulations)
- methotrexate, gold
Overall Schedule
- Tuesday September 4 - 1000 – 1200 – Evaluation of a patient with Asthma/COPD
- Thursday September 6 - 1000 – 1200 – Acute asthma
- Friday September 7 - 0800 – 1100 - Chronic asthma
- Monday September 10 – 0800 - 1000 - Acid-Base – Sean Spina
- Tuesday September 11 – 1000 - 1200 – Smoking Cessation – Sean Spina
- Thursday September 13 – 1000 -1200 – COPD/Pulmonary Therapeutic Beliefs
- Friday September 14 - 0800 – 1100 –Pediatric Asthma – Roxane Carr
Pre-readings and Pre-reading Objectives
** FOR YOUR REFERENCE - NOT TO BE READ FROM BEGINNING TO END
TUESDAY
A) Evaluation and assessment of asthma
Pre-Readings
- Li JT, O’Connell. Clinical evaluation of asthma. Ann Allergy Asthma Immunol 1996;76:1-14
- Aaron SD et al. Overdiagnosis of asthma in obese and nonobese adults. CMAJ 2008;179:1121-31
Specific Pre-reading Objectives
- For reference 1, review Table 1 and be able to discuss clinical features one needs to consider when obtaining a comprehensive history in a patient with asthma
- Discuss the 4 limitations of the clinical evaluation of asthma
B) Drug-induced pulmonary disorders
Pre-Readings
Specific Pre-reading Objectives
- None – this is just for reference purposes
C) Pulmonary function tests, lung exam/breath sounds
Pre-Readings
- Examination of the Chest and Lungs – you can find this at http://medinfo.ufl.edu/year1/bcs/clist/chest.html
- Breath Sounds – you can find this at http://jan.ucc.nau.edu/~daa/heartlung/breathsounds/contents.html Review the breath sounds, adventitious sounds and voice transmission tabs of this website
Specific Pre-reading Objectives
- List the physical exam parameters obtained through inspection, palpation, percussion, and auscultation that would likely be found in patients with asthma, bronchitis, emphysema, and pneumonia.
- Be able to distinguish between wheezes and crackles during auscultation
D) Tests of Pulmonary Function
Pre-readings
- Diagnosis and monitoring. Applied Therapeutics 2005:23-5,6,8 and 9
- Tests of pulmonary function
- McGrath AM, Gardner DM, McCormack J. Is home peak expiratory flow monitoring effective for controlling asthma symptoms? J Clin Pharm Ther 2001; 26:311-317
- Acid-Base Made Simple
Specific Pre-reading Objectives
- Define and identify from a spirogram the various lung volumes (RV, ERV, TV, IRV) and capacities(TLC, VC, FRC, IC)
- Define and identify FEV1, PEFR, FEF25%-75%
- Describe when and how to use a peak flow meter in the treatment of pulmonary disorders
THURSDAY
E) X-ray
Pre-readings
Specific Pre-reading Objectives
- List and describe 5 pieces of information that can be obtained from a chest X-ray
F) Therapeutics of acute asthma (LIKELY FOR THURSDAY), chronic asthma (LIKELY FOR THE FOLLOWING FRIDAY), COPD (LIKELY FOR THE FOLLOWING THURSDAY)
Pre-readings
- Fanta CH. Asthma. N Engl J Med 2009;360:1002-14
- **Expert Panel Report-3 2007 Guidelines for the diagnosis and management of asthma. National Institute of Health
- **Bateman ED et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31:143-78
- **O’Donnell DE et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 update Can Respir J 2007;14(Suppl B):5B-32B
- **Witt TJ et al. Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline. Ann Intern Med. 2007;147:639-53
- **Puhan MA et al. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Medicine 2009;7:2
- LISTEN TO - Therapeutics Education Collaboration Podcast – Smoking cessation Episode 13; COPD - 26,27,39, ASTHMA - 104, 105, 124 IF YOU HAVE TIME – YOU WILL NEED A PREMIUM SUBSCRIPTION – email me once you have signed up on the site (therapeuticseducation.org) and I’ll give you a free one
- Inhaler technique MDI, spacers, diskus, turbuhaler, diskhaler – you can find this at http://www.asthma.ca/adults/treatment/howToUse.php
Specific Pre-reading Objectives
- See overall section objectives – bottom line, please come prepared to discuss the selection and monitoring for drugs used in asthma and COPD